首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity
【24h】

Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity

机译:胶质母细胞瘤中扩增的受体酪氨酸激酶基因以互不相同的比例表现出互斥性,反映了个体肿瘤的异质性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Intratumoral heterogeneity in human solid tumors represents a major barrier for the development of effective molecular treatment strategies, as treatment efficacies will reflect the molecular variegation in individual tumors. In glioblastoma, the generation of composite genomic profiles from bulk tumor samples has allowed one to map the genomic amplifications of putative genetic drivers and to prioritize therapeutic targeting strategies aimed at eradicating the tumor burden. Notably, amplification of multiple receptor tyrosine kinases (RTK) within a single tumor specimen obtained from patients is frequently observed. In this study, use of a detailed multicolor FISH mapping procedure in pathologic specimens revealed a mutual exclusivity of gene amplification in the majority of glioblastoma tumors examined. In particular, the two most commonly amplified RTK genes, EGFR and PDGFRA, were found to be present in variable proportions across the tumors, with one or the other gene predominating in certain areas of the same specimen. Our findings have profound implications for designing efficacious therapeutic regimens, as it remains unclear that how the cells with different gene amplification events contribute to disease propagation or the response to molecular targeted therapies.
机译:人类实体瘤中的肿瘤内异质性代表了有效分子治疗策略发展的主要障碍,因为治疗效果将反映单个肿瘤​​中的分子变异。在胶质母细胞瘤中,从大量肿瘤样品中产生复合基因组图谱已经使人们能够绘制推定的遗传驱动因子的基因组扩增图,并优先考虑旨在消除肿瘤负担的治疗靶向策略。值得注意的是,经常观察到从患者获得的单个肿瘤样品中多个受体酪氨酸激酶(RTK)的扩增。在这项研究中,在病理标本中使用详细的多色FISH定位程序揭示了在大多数检测的胶质母细胞瘤肿瘤中基因扩增的相互排斥性。特别是,发现两个最普遍扩增的RTK基因EGFR和PDGFRA在整个肿瘤中存在不同的比例,而一个或另一个基因在同一样本的某些区域占主导地位。我们的发现对设计有效的治疗方案具有深远的意义,因为尚不清楚具有不同基因扩增事件的细胞如何促进疾病传播或对分子靶向疗法的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号